Comparison of two different treatment regimens’ efficacy in neovascular age-related macular degeneration in Turkish population—based on real life data-Bosphorus RWE Study Group

AIM: To compare two different anti-vascular endothelial growth factor (anti-VEGF) treatment regimens’-a priori pro re nata (PRN) and PRN regimen following the loading phase-anatomical and functional results in neovascular age-related macular degeneration (nAMD) patients. METHODS: Totally 544 nAMD p...

Full description

Bibliographic Details
Published in:	International Journal of Ophthalmology
Main Authors:	Burak Erden, Selim Bölükbaşı, Abdullah Özkaya, Levent Karabaş, Cengiz Alagöz, Zeynep Alkın, Özgür Artunay, Sadık Etka Bayramoğlu, Gökhan Demir, Mehmet Demir, Ali Demircan, Gürkan Erdoğan, Mehmet Erdoğan, Erdem Eriş, Havva Kaldırım, İsmail Umut Onur, Özen Ayrancı Osmanbaşoğlu
Format:	Article
Language:	English
Published:	Press of International Journal of Ophthalmology (IJO PRESS) 2020-01-01
Subjects:	aflibercept neovascular age-related macular degeneration ranibizumab loading dose treatment regimen
Online Access:	http://www.ijo.cn/en_publish/2020/1/20200115.pdf

Similar Items

Real-World Outcomes of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration in Turkey: A Multicenter Retrospective Study, Bosphorus Retina Study Group Report No: 1
by: Abdullah Özkaya, et al.
Published: (2018-10-01)

Comparison of the effects of 3 different anti-VEGF drugs on cornea thickness, lens thickness and anterior chamber depth
by: Mehmet Tahir Eski, et al.
Published: (2023-03-01)

Endophthalmitis following intravitreal injections at a tertiary center: real-life data on incidence, risk factors, management strategies, and visual outcomes
by: Sebile Comcali, et al.
Published: (2025-05-01)

Incidence of endophthalmitis after intravitreal application of anti VEGF therapy at the University Clinical Center in Tuzla, Bosnia and Herzegovina
by: Svjetlana Terzić, et al.
Published: (2015-08-01)

Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration
by: Bhagya Weerasinghe, et al.
Published: (2021-01-01)

Clinical Outcomes and Experiences with Prefilled Syringes Versus Vials for Intravitreal Administration of Anti-VEGF Treatments: A Systematic Review
by: Joel Uzzan, et al.
Published: (2024-07-01)

Aflibercept monotherapy or bevacizumab first for diabetic macular edema
by: Avner Hostovsky, et al.
Published: (2024-01-01)

Comparison of the efficacy of intravitreal Anti-VEGF versus intravitreal dexamethasone implant in treatment resistant diabetic Macular Edema
by: Hakan Koc, et al.
Published: (2023-03-01)

The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis
by: Jing Chen, et al.
Published: (2023-10-01)

Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature
by: Irini Chatziralli, et al.
Published: (2021-07-01)

Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01)

Incidence and Clinical Practice of Myopic Macular Neovascularization: A Nationwide Population-Based Cohort Study
by: Masahiro Akada, MD, et al.
Published: (2025-11-01)

Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study
by: Chakraborty D, et al.
Published: (2024-11-01)

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
by: Flora Elwes, et al.
Published: (2018-01-01)

Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience
by: Mahmut Kaya, et al.
Published: (2023-02-01)

A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents
by: Kiran Turaka
Published: (2014-04-01)

Transitioning from Aflibercept to Biosimilar Ranibizumab in Neovascular AMD (The TRANSFORM Trial): A Multicenter Observational Study
by: Chakraborty D, et al.
Published: (2024-06-01)

Comparison of Two-Year Outcome of Photodynamic Therapy in Combination with Intravitreal Aflibercept or Ranibizumab for Polypoidal Choroidal Vasculopathy
by: Hsin-Yu Weng, et al.
Published: (2021-01-01)

Fracionamento de seringas intravítreas de aflibercept e ranibizumab, utilizando técnica assética
by: Rita Gomes, et al.
Published: (2024-05-01)

Comparison of ranibizumab, aflibercept, and dexamethasone implant monotherapy in treatment-naive eyes with diabetic macular edema: A 12-month real-life experience
by: Osman Parca, et al.
Published: (2024-03-01)

Aflibercept vs. dexamethasone implant for recalcitrant diabetic macular edema in pseudophakic eyes – 1-year outcomes from a quazi-randomized study in India
by: Debdulal Chakraborty, et al.
Published: (2024-04-01)

Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis
by: Xian Wang, et al.
Published: (2022-06-01)

Systemic effects of anti-VEGF intravitreal injection in patients with age-related macular degeneration: A multi-institutional real-world study
by: Tzu-Yi Lin, et al.
Published: (2024-11-01)

Diversity when interpreting evidence in network meta-analyses (NMAs) on similar topics: an example case of NMAs on diabetic macular oedema
by: Jing Wu, et al.
Published: (2023-10-01)

Biomarkers as Predictive Factors of Anti-VEGF Response
by: Miriam Bobadilla, et al.
Published: (2022-04-01)

Intravitreal vascular endothelial growth factor inhibitors did not increase the risk of end-stage renal disease in patients with biopsy-proven diabetic kidney disease based on matched study
by: Xiang Xiao, et al.
Published: (2022-12-01)

Pharmacokinetic Simulations of Intravitreal Biologicals: Aspects of Drug Delivery to the Posterior and Anterior Segments
by: Anna-Kaisa Rimpelä, et al.
Published: (2018-12-01)

Intravitreal Ranibizumab for Diabetic Macular Edema Patients with Good Baseline Visual Acuity: A Real-Life Study
by: Abdullah Ozkaya, et al.
Published: (2017-10-01)

Survey of Intravitreal Injection Preferences for the Treatment of Age-Related Macular Degeneration and Macular Edema Among Members of the Turkish Ophthalmological Association
by: V. Levent Karabaş, et al.
Published: (2022-06-01)

Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice
by: R. R. Fayzrakhmanov
Published: (2019-06-01)

Intravitreal Antiangiogenic Treatment for Diabetic Retinopathy: A Mexican Real-Life Scenario Experience
by: Sonia López-Letayf, et al.
Published: (2024-08-01)

Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs
by: Małgorzata Figurska, et al.
Published: (2021-12-01)

Macular Ischemia Changes in Patients with Diabetic Macular Edema Treated with Aflibercept and Ranibizumab
by: Dimitrios Maris, et al.
Published: (2024-06-01)

Differences between pathologic and non-pathologic high myopia in 4-year outcomes of anti-VEGF therapy for macular neovascularization
by: Yuki Honda, et al.
Published: (2024-06-01)

Different approaches for treating myopic choroidal neovascularization: a network Meta-analysis
by: Ya-Jun Wu, et al.
Published: (2023-12-01)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
by: Alsaedi NG, et al.
Published: (2021-07-01)

THE EFFICACY AND SAFETY PROFILE OF ADVANCED THERAPY MEDICINAL PRODUCTS IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION
by: R. N. Alyautdin, et al.
Published: (2022-05-01)

Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study
by: Mekala Shellvarajah, et al.
Published: (2025-04-01)

Efficacy, Safety, and Treatment Burden of Aflibercept 2 mg and Ranibizumab in Retinal Vein Occlusion: A Systematic Review and Meta-analysis
by: Jing Wu, et al.
Published: (2024-03-01)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
by: Dorota Luksa, et al.
Published: (2021-11-01)